SEROPROTECTION AGAINST VACCINE-PREVENTABLE INFECTIONS IN CAR T-CELL RECIPIENTS: LOWER BASELINE TITERS IN BCMA- VERSUS CD19-CAR T PATIENTS PERSIST AFTER THERAPY
EHA Library, Giulia Magno, 4206866
PRIMARY PROPHYLAXIS WITH IMMUNOGLOBULIN-REPLACEMENT THERAPY IMPROVES INFECTION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH B-CELL MATURATION ANTIGEN BISPECIFIC ANTIBODIES
EHA Library, Antoine Azar, 4206867
SICKLE CELL DISEASE IN EUROPE: A CROSS-BORDER REAL-WORLD DATA ANALYSIS FROM THE RADEEP REGISTRY
EHA Library, Anna Collado Gimbert, 4206846
RESULTS OF THE PHASE 1B PIONEER STUDY: SAFETY AND EFFICACY OF POCIREDIR IN ADULTS WITH SEVERE SICKLE CELL DISEASE AND HYDROXYUREA INTOLERANCE OR UNRESPONSIVENESS
EHA Library, Modupe Idowu, 4206845
PHASE 1/2 HIBISCUS KIDS STUDY OF ETAVOPIVAT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE: SAFETY AND EFFICACY FINDINGS FROM THE COMPLETE FIRST COHORT
EHA Library, Bernhards Ogutu, 4206844
VENETOCLAX SENSITIVITY IN ACUTE MYELOID LEUKAEMIA WITH RUNX1 FRAMESHIFT MUTATIONS RESULTS FROM MITOCHONDRIAL ADAPTATION TO PROTEOSTATIC STRESS
EHA Library, David Palmer, 4206675
CYTOPLASMIC LOCALIZATION OF QKI MEDIATES THERAPUETIC RESISTANCE AND IMMUNE EVASION
EHA Library, Sadik Karma, 4206676
TRANSCRIPTIONALLY DEFINED AML CELL STATES ASSOCIATE WITH TREATMENT RESPONSE AND MICROENVIRONMENTAL REMODELING
EHA Library, Nona Struyf, 4206678
ZIFTOMENIB COMBINED WITH INTENSIVE INDUCTION (7+3) FOR NEWLY DIAGNOSED NPM1‑M OR KMT2A-R ACUTE MYELOID LEUKEMIA (AML): LONG-TERM RESULTS FROM THE KOMET-007 TRIAL
EHA Library, Amer M. Zeidan, 4206684
A PHASE II RANDOMIZED STUDY OF AK117 VERSUS PLACEBO IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
EHA Library, Huafeng Wang, 4206685
HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH HIGH-RISK ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ARSENIC TRIOXIDE. RESULTS FROM THE INTERNATIONAL RANDOMIZED PHASE III APOLLO TRIAL
EHA Library, Fabio Efficace, 4206686
TUSCANY STUDY OF SAFETY AND EFFICACY OF TUSPETINIB PLUS STANDARD OF CARE VENETOCLAX AND AZACITIDINE IN STUDY PARTICIPANTS WITH NEWLY DIAGNOSED AML INELIGIBLE FOR INDUCTION CHEMOTHERAPY
EHA Library, Nikolai Podoltsev, 4206688
UPDATED EFFICACY AND SAFETY DATA FROM AN ONGOING PHASE 1A/B TRIAL OF THE BTK DEGRADER BEXOBRUTIDEG (NX-5948) IN PATIENTS WITH CLL ACROSS LINES OF THERAPY
EHA Library, Talha Munir, 4206704
OUTCOMES OF VENETOCLAX-BASED TREATMENT IN PATIENTS WITH BRUTON TYROSINE KINASE INHIBITOR (BTKI)-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): AN INTERNATIONAL STUDY CONDUCTED BY ERIC
EHA Library, Thomas Chatzikonstantinou, 4206705
BGB-16673, A BRUTON TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): A PHASE 1 CADANCE-101 STUDY UPDATE
EHA Library, Stephan Stilgenbauer, 4206706
DUAL TARGETED LENTIVIRAL TRANSDUCED ANTI-CD20/ANTI-CD19 (LV20.19) CAR T CELLS FOR RELAPSED, REFRACTORY CLL
EHA Library, Nirav N Shah, 4206708
PRE‑TRANSPLANT BLINATUMOMAB AND CAR‑T SHAPE IMMUNE RECONSTITUTION DYNAMICS IN CHILDREN
EHA Library, Silvia Nucera, 4206843
DURABLE CLINICAL BENEFITS WITH RM001 (AUTOLOGOUS HBG1/2 PROMOTER-MODIFIED CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS) FOR TRANSFUSION-DEPENDENT Β-THALASSEMIA
EHA Library, Hui Xu, 4206842
DURABLE RESPONSES AND FAVORABLE SAFETY OF BAFF-R CAR T-CELLS (PMB-CT01) IN PATIENTS WITH RELAPSED/ REFRACTORY B-CELL LYMPHOMAS WITH PRIOR CD19-DIRECTED THERAPY FAILURE OR CD19-NEGATIVE DISEASE
EHA Library, L. Elizabeth Budde, 4206841
CSNK1A1 E98V DRIVES REWIRING OF SIGNALLING AND METABOLISM IN DEL(5Q) MDS
EHA Library, Juliette Pearce, 4206720
LARGE-SCALE SCREENING OF MYELOID NEOPLASTIC PRECURSOR STATES USING BLOOD CELL MORPHOLOGY
EHA Library, Oona RInkinen, 4206721
SELECTIVE EXPANSION OF TET2‑MUTANT CLONAL HEMATOPOIESIS UNDER METFORMIN IS DRIVEN BY ENHANCED MITOCHONDRIAL AND LIPID STRESS TOLERANCE
EHA Library, Silke E. Miedema, 4206722
GENOMIC LANDSCAPE AND PROGNOSTIC IMPACT OF SOMATIC MUTATIONS IN APLASTIC ANEMIA PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Library, Xiao-Di Ma, 4206734
ELTROMBOPAG ADDED TO COMBINED IMMUNOSUPPRESSIVE THERAPY (IST) IN CHILDREN WITH ACQUIRED SEVERE APLASTIC ANEMIA ACCELERATES HEMATOLOGIC RECOVERY AND SHOULD BE CONTINUED IN THE SECOND COURSE OF IST
EHA Library, Alexey Maschan, 4206736
ELTROMBOPAG PLUS CYCLOSPORINE A FOR MODERATE APLASTIC ANEMIA (EMAA), A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED PHASE 3 TRIAL: TREATMENT MODIFICATIONS AFTER DOUBLE BLIND TREATMENT PERIOD
EHA Library, Britta Höchsmann, 4206738
OL-101, A BCMA/GPRC5D DUAL-TARGETING CAR-T, INDUCES DEEP RESPONSES IN HEAVILY PRETREATED ADVANCED MYELOMA, PARTICULARLY IN PATIENTS POST BCMA- OR GPRC5D-TARGETED THERAPY OR WITH EXTRAMEDULLARY DISEASE
EHA Library, Mingming Zhang, 4206839
MOLECULAR SURVEILLANCE OF AGGRESSIVE LARGE B-CELL LYMPHOMA USING CIRCULATING TUMOR DNA DUPLEXES
EHA Library, Sirpa Leppä, 4206813
INTEGRATED CLINICAL AND GENETIC SCORING REFINES PROGNOSIS IN DARK ZONE SIGNATURE-POSITIVE (DZSIGPOS) DIFFUSE LARGE B-CELL LYMPHOMA: THE DARK ZONE PROGNOSTIC INDEX (DZPI)
EHA Library, Jinhua Liang, 4206812
TUMOR CELL EXPRESSION OF SOX11 AND CYCLIN D1 DIFFERENTLY IMPACT THE SPATIAL TUMOR IMMUNE CELL LANDSCAPE IN MANTLE CELL LYMPHOMA- A TRANSLATIONAL NORDIC MCL2/3 STUDY
EHA Library, June Myklebust, 4206788
CLINICAL IMPACT OF GERMLINE SINGLE-NUCLEOTIDE POLYMORPHISMS IN MANTLE CELL LYMPHOMA: INSIGHTS FROM THE TRIANGLE TRIAL BY THE MULTIPLY CONSORTIUM
EHA Library, Bashar Al Deeban, 4206785
GENOMIC PREDICTORS OF OUTCOME IN MANTLE CELL LYMPHOMA: TP53 AND ADDITIONAL ALTERATIONS IN THE TRIANGLE TRIAL BY THE MULTIPLY CONSORTIUM
EHA Library, Marta Grau, 4206787
FIXED-DURATION GLOFITAMAB MONOTHERAPY IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA WITH OR WITHOUT PRIOR BRUTON'S TYROSINE KINASE INHIBITOR EXPOSURE: UPDATED OUTCOMES WITH 3.5 YEARS OF FOLLOW-UP
EHA Library, Yasmin Karimi, 4206786
CD22-DIRECTED CAR T-CELLS INDUCE HIGH RATES OF COMPLETE REMISSIONS WITH MINIMAL NEUROTOXICITY IN HIGH-RISK FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, AND OTHER NON-HODGKIN LYMPHOMA SUBTYPES.
EHA Library, Matthew J. Frank, 4206784
HIGH MRD NEGATIVITY RATES AND PROLONGED PFS WITH BELANTAMAB MAFODOTIN PLUS DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE NEWLY-DIAGNOSED MYELOMA: RESULTS OF THE BELA-DRD STUDY
EHA Library, Evangelos Terpos, 4206758
CB-011, AN ALLOGENEIC ANTI-BCMA CAR-T CELL THERAPY WITH IMMUNE CLOAKING, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (CAMMOUFLAGE PHASE 1 TRIAL)
EHA Library, Binod Dhakal, 4206755
DYNAMICS AND CLINICAL IMPACT OF CLONAL HEMATOPOIESIS IN DIFFUSE LARGE B-CELL LYMPHOMA THROUGH MULTI-COMPARTMENT GENOMIC PROFILING
EHA Library, Nawar Maher, 4206809
CIRCULATING TUMOR DNA REVEALS LYMPHOMA-ASSOCIATED MUTATIONS LONG BEFORE CLINICAL DIAGNOSIS
EHA Library, Nick Veltmaat, 4206810
DIAGNOSING PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA THROUGH MOLECULAR AND IMMUNE BIOMARKERS IN CEREBROSPINAL FLUID: A MULTICENTRE PROSPECTIVE COHORT STUDY (PRICELUS)
EHA Library, Josephus van Rooij, 4206811
ARLOCABTAGENE AUTOLEUCEL, A GPRC5D-TARGETED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1 SAFETY AND EFFICACY RESULTS IN PATIENTS WITH 1–3 PRIOR REGIMENS
EHA Library, Susan Bal, 4206754
CLINICAL AND MOLECULAR FINDINGS IN 46 PATIENTS WITH DNAJC21-RELATED BONE MARROW FAILURE SYNDROME
EHA Library, María Muñoz Martínez, 4206737
A PHASE III STUDY OF A HEAD-TO-HEAD COMPARISON OF A FACTOR B INHIBITOR HSK39297, VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAIVE TO COMPLEMENT INHIBITION
EHA Library, Yawen Zhang, 4206735
GENOMIC ANALYSIS OF PRELEUKEMIC CLONES IDENTIFIES NEW DRIVERS OF MYELOID NEOPLASMS
EHA Library, Martina Sarchi, 4206723
A NEW MOUSE MODEL OF JMML HIGHLIGHTS DIFFERENTIAL SUSCEPTIBILITY OF EMBRYONIC HEMATOPOIETIC STEM/PROGENITOR CELLS TO ONCOGENIC KRASG12D AND IDENTIFIES INFLAMMATION AS A TARGETABLE THERAPEUTIC AXIS
EHA Library, Emanuele Azzoni, 4206719
FIXED DURATION VENETOCLAX PLUS EPCORITAMAB SHOWS FAVORABLE TOLERABILITY AND HIGH RESPONSE RATES WITH EARLY MOLECULAR RESPONSES IN R/R CLL/SLL: INTERIM ANALYSIS OF THE RANDOMIZED HOVON 165/AETHER TRIAL
EHA Library, Arnon Philip Kater, 4206707
CD19/CD22 BISPECIFIC CAR-T CELL THERAPY FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AND MECHANISTIC INVESTIGATION: A PROSPECTIVE, SINGLE-ARM, SINGLE-CENTER, PHASE 2 CLINICAL TRIAL
EHA Library, Liang Wang, 4206840
IN HUMANIZED SICKLE CELL MICE, COLCHICINE PROTECTS AGAINST THE PROGRESSION OF SICKLE CELL CARDIOMYOPATHY
EHA Library, Enrica Federti, 4206847
A PLASMA–PLACENTAL ATLAS OF SICKLE CELL PREGNANCY REVEALS ENDOTHELIAL, COAGULATION, AND COMPLEMENT DYSREGULATION
EHA Library, Alexandra Boye-Doe, 4206848
INTENSIVE CHEMOTHERAPY IN COMBINATION WITH QUIZARTINIB VERSUS MIDOSTAURIN FOR FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA: A MULTICENTER COHORT STUDY
EHA Library, Michelle Lee, 4206687
TEMPORAL TRENDS IN INFECTION-RELATED PROPORTIONAL MORTALITY IN LYMPHOMA: A DANISH POPULATION-BASED STUDY
EHA Library, William Mølgaard Ullahammer, 4206864
HIGH-DOSE VERSUS STANDARD-DOSE INACTIVATED INFLUENZA VACCINE IN OLDER ADULTS WITH HEMATOLOGICAL MALIGNANCIES: SUBGROUP ANALYSIS FROM THE DANFLU-2 RANDOMIZED TRIAL
EHA Library, Christian Brieghel, 4206865
EARLY PROPHYLACTIC RITUXIMAB REDUCED THE INCIDENCE OF EBV INFECTION AND PTLD IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTER STUDY
EHA Library, Ao Zhang, 4206868
ENFORCING FATTY ACID SATURATION IMBALANCE ENHANCES STEAROYL-COA DESATURASE INHIBITION THERAPEUTIC EFFICACY IN ACUTE MYELOID LEUKEMIA
EHA Library, Sirisha Natani, 4206677
A CD22 ANTIGEN SHIFT OCCURS IN VENETOCLAX/AZACITIDINE RESISTANT AML AND FACILITATES TARGETED THERAPY
EHA Library, Josephine Brysting, 4206674
COMPARISON OF END INDUCTION FLOW CYTOMETRY VERSUS HIGH-THROUGHPUT SEQUENCING BASED MINIMAL RESIDUAL DISEASE IN NEWLY DIAGNOSED CHILDHOOD STANDARD RISK B ALL:  A REPORT FROM COG AALL1731
EHA Library, Sumit Gupta, 4206666
IMPROVING EFFICACY AND SAFETY OUTCOMES IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN MORPHOLOGIC REMISSION TREATED WITH OBECABTAGENE AUTOLEUCEL (OBE-CEL)
EHA Library, Claire Roddie, 4206667
SAFETY AND EFFICACY OF UCART22 IN HEAVILY PRE-TREATED PATIENTS WITH RELAPSED OR REFRACTORY CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): RESULTS OF THE PHASE 1 BALLI-01 TRIAL
EHA Library, Nitin Jain, 4206668
CD5 INHIBITION AS A GENERALIZABLE STRATEGY TO AMPLIFY T CELL-MEDIATED ANTI-TUMOR EFFECTS OF BISPECIFIC T-CELL ENGAGERS
EHA Library, Weilin Wang, 4206658
TAFASITAMAB PLUS LENALIDOMIDE AND R-CHOP FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS FROM THE PHASE 3 FRONTMIND STUDY
EHA Library, Georg Lenz, 4206655
ETAVOPIVAT IMPROVES HEMOGLOBIN LEVELS IN ADULTS AND ADOLESCENTS WITH NON-TRANSFUSION-DEPENDENT ALPHA- OR ΒETA-THALASSEMIA: RESULTS FROM THE OPEN-LABEL PHASE 2 GLADIOLUS STUDY
EHA Library, Sujit Sheth, 4206851
SENESCENCE AND INFLAMMATION ARE UNINTENDED ADVERSE CONSEQUENCES OF CRISPR-CAS9/AAV6-MEDIATED GENE EDITING IN HEMATOPOIETIC STEM CELLS
EHA Library, Anastasia Conti, 4206836
SINGLE-CELL TRANSCRIPTOMICS-GUIDED FLOW CYTOMETRIC ANALYSIS OF INFLAMED MEGAKARYOCYTIC AND LYMPHOID PROGENITORS AT DIAGNOSIS IDENTIFIES CHRONIC PHASE CML AT HIGH RISK FOR BLAST CRISIS TRANSFORMATION
EHA Library, Tiong Ong, 4206710
MOLECULAR MECHANISM OF ZDHHC19-MEDIATED JAK1 PALMITOYLATION DRIVING TKIS RESISTANCE IN CML LEUKEMIA STEM CELLS
EHA Library, Teng Wang, 4206712
ALLOGENEIC HSCT FOR TP53-ABERRANT MYELOID NEOPLASMS: REAL-WORLD OUTCOMES FROM A SCANDINAVIAN MULTICENTRE COHORT
EHA Library, Anders Eivind Myhre, 4206827
LACK OF PROGNOSTIC IMPACT OF FLT3-ITD ON ALLOGENEIC TRANSPLANTATION OUTCOME IN AML WITH INV (16) (P13.1; Q22.1) OR T (16;16) (P13.1; Q22.1) ;(CBFB::MYH11): A STUDY ON BEHALF OF THE ALWP OF THE EBMT
EHA Library, Arnon Nagler, 4206826
POST-TRANSPLANT DYNAMICS OF DTA MUTATIONS AND THEIR ASSOCIATION WITH MOLECULAR RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
EHA Library, Corinne Widmer, 4206824
7-KETOCHOLESTEROL REPROGRAMS T-CELL LINEAGE METABOLISM TO AMELIORATE STEROID-REFRACTORY ACUTE GVHD
EHA Library, Qingxiao Song, 4206816
DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF TRANSPLANT-INELIGIBLE PATIENTS IN THE PHASE 3 CEPHEUS STUDY
EHA Library, Saad Z Usmani, 4206750
TECLISTAMAB PLUS DARATUMUMAB (TEC-DARA) IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): ANALYSIS OF MAJESTEC-3 BASED ON CYTOGENETIC AND FUNCTIONAL RISK
EHA Library, Rahul Banerjee, 4206752
INTEGRATIVE MULTIMODAL PROFILING OF THE MICROBIOME-IMMUNE AXIS IN AUTOLOGOUS STEM CELL RECIPIENTS
EHA Library, Sabrina Becker, 4206815
TUMOR MICROENVIRONMENT WITH VASCULATURE-DRIVEN T-CELL EXHAUSTION IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA REVEALED BY SINGLE-CELL SPATIAL MULTI-OMICS
EHA Library, Yuki Shimizu, 4206807
CD20:CD3 T-CELL BISPECIFIC ANTIBODIES REPROGRAM THE TUMOR MICROENVIRONMENT AND SYNERGIZE WITH LYMPHOMA-TARGETED 4-1BB CO-STIMULATION IN PRECLINICAL DLBCL MODELS
EHA Library, Sergio Roa, 4206806
EFFICACY AND SAFETY OF LUSPATERCEPT IN PATIENTS WITH MYELOFIBROSIS ON JANUS KINASE INHIBITORS WHO REQUIRE RED BLOOD CELL TRANSFUSIONS: PRIMARY ANALYSIS OF THE PHASE 3 INDEPENDENCE TRIAL
EHA Library, Francesco Passamonti, 4206769
EARLY VERSUS DELAYED INITIATION OF ROPEGINTERFERON ALFA-2B IN HIGH-RISK ESSENTIAL THROMBOCYTHAEMIA: TWO-YEAR RESULTS FROM THE PHASE 3 SURPASS-ET STUDY
EHA Library, Harinder gILL, 4206773
BRAIN-LYM: DEFINING IMMUNE-MOLECULAR PHENOTYPES IN PRIMARY CNS LYMPHOMA
EHA Library, Fleur de Groot, 4206804
COMPREHENSIVE ANALYSIS OF BRIDGING TO CAR T-CELL THERAPY IN LARGE B-CELL LYMPHOMA WITH CONVENTIONAL TREATMENT OR CD3XCD20 BISPECIFIC ANTIBODIES
EHA Library, Ruth Fluemann, 4206795
RESULTS OF AJX-101, A PHASE 1 CLINICAL TRIAL OF THE TYPE II JAK2 INHIBITOR AJ1-11095, IN PATIENTS WITH MYELOFIBROSIS WHO HAVE BEEN FAILED BY A TYPE I JAK2 INHIBITOR
EHA Library, John Mascarenhas, 4206772
FAVORABLE REAL-WORLD OUTCOMES AFTER CD19 CAR T CELL TREATMENT IN RELAPSED/REFRACTORY HIGH-GRADE B-CELL LYMPHOMAS (HGBL): AN EBMT LWP ANALYSIS
EHA Library, Igor Age Kos, 4206797
TUMOUR MICROENVIRONMENT ARCHETYPES THAT SUPPORT ANTI-TUMOUR T-CELL IMMUNITY AND CD4⁺ T-CELL CYTOTOXIC DIFFERENTIATION UNDERPIN RESPONSE TO GLOFITAMAB IN DIFFUSE LARGE B-CELL LYMPHOMA
EHA Library, Thiago M Steiner, 4206798
HMGA1 STABILIZES MYC PROTEIN TO DRIVE ONCOGENIC TRANSCRIPTIONAL PROGRAMS IN TRANSFORMED FOLLICULAR LYMPHOMA (FL)
EHA Library, Androniki Michaelou, 4206808
MUTANT CALRETICULIN–SPECIFIC MONOCLONAL ANTIBODY, INCA033989, IS WELL TOLERATED AND ACHIEVES ROBUST SPLEEN, ANEMIA, AND MOLECULAR RESPONSES IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
EHA Library, Claire HARRISON, 4206770
TECLISTAMAB  (TEC) +/- LENALIDOMIDE (LEN) VERSUS LEN ALONE AS MAINTENANCE THERAPY POST-TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED SAFETY RUN-IN (SRI) RESULTS FROM EMN30/MAJESTEC-4
EHA Library, Niels W. C. J. van de donk, 4206751
INTEGRATED METABOLIC AND EPIGENETIC PROFILING UNCOVERS DISTINCT IMMUNE‑ESCAPE PROGRAMS AND TARGETABLE VULNERABILITIES IN POST‑TRANSPLANT AML RELAPSE
EHA Library, Annalisa Tameni, 4206814
TRIM5 DRIVES T CELL PATHOGENICITY IN GRAFT-VERSUS-HOST DISEASE THROUGH SLC25A35 UBIQUITINATION
EHA Library, Qiao Cheng, 4206817
A LIVING THERAPEUTIC PLATFORM FOR LOCALIZED IN SITU MODULATION OF MACROPHAGE PYROPTOSIS AMELIORATES GVHD WHILE PRESERVING GVL
EHA Library, Zhuo Wan, 4206818
REFINING PROGNOSTIC STRATIFICATION FOR SAML POST-ALLO-HSCT: VALIDATION OF ELN 2022 AND PREDOMINANT ROLE OF MDS-RELATED CYTOGENETICS.
EHA Library, Nan Yang, 4206825
A GENETIC–CLINICAL PROGNOSTIC ALGORITHM FOR RISK STRATIFICATION IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA UNDERGOING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Library, Yue Jin, 4206828
MULTIPLEX PRIME EDITING ENABLES SAFE, DRUG-CONTROLLABLE, AND IMMUNOSUPPRESSION-RESISTANT T-CELL THERAPIES
EHA Library, Thomas Lew, 4206834
INTEGRATED MULTI-OMIC PROFILING IDENTIFIES GENOMIC SUBTYPES ASSOCIATED WITH DIFFERENTIAL OUTCOMES AFTER CAR-T THERAPY IN LARGE B-CELL LYMPHOMA
EHA Library, Silvia Escribano Serrat, 4206837
BRANCHED-CHAIN AMINO ACID BIOAVAILABILITY DURING CD19 CAR T-CELL EXPANSION ASSOCIATES WITH FAVORABLE T-CELL STATES AND CLINICAL RESPONSE IN LBCL
EHA Library, Sylvain Lamure, 4206838
MAJESTEC-9: A PHASE 3 STUDY OF TECLISTAMAB MONOTHERAPY VS POMALIDOMIDE/BORTEZOMIB/DEXAMETHASONE OR CARFILZOMIB/DEXAMETHASONE (PVD/KD) IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Library, Cyrille Touzeau, 4206749
INTEGRATED GENOMIC AND TRANSCRIPTOMIC ANALYSES REVEAL BIOLOGICAL HETEROGENEITY OF ACCELERATED-PHASE CHRONIC MYELOID LEUKEMIA AND IDENTIFY A BLAST-PHASE-LIKE SUBGROUP
EHA Library, Xiaoshuai Zhang, 4206713
INFLUENCE OF NON-BCR::ABL1 SOMATIC MUTATIONS ON TYROSINE KINASE INHIBITOR (TKI) RESISTANCE IN CHRONIC MYELOID LEUKEMIA
EHA Library, Michele Ciboddo, 4206711
SINGLE-CELL GENETIC LINEAGE TRACING REVEALS PRE-EXISTING BLAST CRISIS-INITIATING CLONES AT CHRONIC PHASE CML DIAGNOSIS
EHA Library, Elaine Cao, 4206709
ANTIBODY-BASED IMMUNOTHERAPY VERSUS CELLULAR THERAPY AS BRIDGING TO ALLOGENEIC STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY OR MRD-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Library, Ao-ran Zhang, 4206665
LONG-TERM OUTCOMES OF NATURALLY SELECTED CD7 CAR-T THERAPY IN RELAPSED/REFRACTORY T-LYMPHOBLASTIC LEUKEMIA/LYMPHOMA: A COHORT OF 171 PATIENTS
EHA Library, Xian Zhang, 4206664
REPLACEMENT OF HIGH DOSE COMBINATION CHEMOTHERAPY WITH BLINATUMOMAB IN NEWLY DIAGNOSED PEDIATRIC HIGH-RISK B-CELL ALL IMPROVES EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 AIEOP-BFM ALL 2017 TRIAL
EHA Library, Martin Schrappe, 4206657
EFFICACY AND SAFETY OF ORAL TETRAHYDROURIDINE-DECITABINE (NDEC) IN ADULTS WITH SICKLE CELL DISEASE: RESULTS FROM THE PHASE 2, GLOBAL, RANDOMIZED, PARALLEL-GROUP ASCENT1 TRIAL
EHA Library, Biree Andemariam, 4206849
LONG-TERM HEMOGLOBIN IMPROVEMENTS IN NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA: RESULTS FROM THE OPEN-LABEL EXTENSION OF THE ONGOING PHASE 3 ENERGIZE TRIAL
EHA Library, Hanny Al-Samkari, 4206850
EFFICACY AND SAFETY OF MITAPIVAT IN SICKLE CELL DISEASE: RESULTS FROM THE GLOBAL, RANDOMIZED, PHASE 3 RISE UP TRIAL
EHA Library, Biree Andemariam, 4206656
PHASE 3, RANDOMIZED STUDY OF TALQUETAMAB (TAL) PLUS DARATUMUMAB (DARA) ± POMALIDOMIDE (POM) VS DARA PLUS POM AND DEXAMETHASONE (DPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): MONUMENTAL-3
EHA Library, Peter Voorhees, 4206654

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings